Targeting Inflammation in Atherosclerotic Cardiovascular Disease: Mechanisms and Emerging Therapies
Immunological Reviews · 2026-08 · 341 (1)
DOI: 10.1111/imr.70151 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunological Reviews, online erschienen am 29.07.2026. Verfasst von M P Spindler und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Atherosclerosis, Inflammation, Anti-Inflammatory Agents, Cardiovascular Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 156 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
A large body of evidence has helped reframe atherosclerotic cardiovascular disease from a mere lipid storage disorder to a chronic inflammatory disease. Both innate and adaptive immune pathways contribute to atherogenesis, plaque progression, and plaque destabilization. Macrophages, T cells, and cytokines—among them IL‐1β, IL‐6, and IL‐18—have emerged as key immune cells and mediators implicated in atherosclerosis progression. Residual inflammatory risk—as measured by highly sensitive C‐reactive protein (hsCRP) – has gained broad clinical acceptance as an important biomarker of cardiovascular risk prediction independent of cholesterol burden. Finding strategies that target residual inflammatory risk has proven an elusive goal in preventative cardiology. Specific approaches—such as IL‐1β inhibition or low‐dose colchicine—have shown benefit in reducing cardiovascular events, while other strategies have failed, underscoring the importance of targeting disease‐relevant immune pathways and selecting patients that will benefit. Newer approaches—including IL‐6 inhibitors, NLRP3 inflammasome inhibitors, and low‐dose IL‐2—offer promise for further risk reduction. Efforts to use inflammatory biomarkers to more precisely identify patients who may benefit may further improve the benefit‐to‐risk profile of emerging therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Heart and Vascular Institute, Mass General Brigham Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Boston, Massachusetts, USA.
ORCID-Profile: M P Spindler, P Libby
Zitieren
APA
Spindler, M. P., Libby, P., & Ridker, P. M. (2026). Targeting Inflammation in Atherosclerotic Cardiovascular Disease: Mechanisms and Emerging Therapies. Immunological Reviews, 341(1). https://doi.org/10.1111/imr.70151
Vancouver
Spindler MP, Libby P, Ridker PM. Targeting Inflammation in Atherosclerotic Cardiovascular Disease: Mechanisms and Emerging Therapies. Immunological Reviews. 2026;341(1). doi:10.1111/imr.70151
BibTeX
@article{Spindler2026,
author = {Spindler, M P and Libby, P and Ridker, P M},
title = {Targeting Inflammation in Atherosclerotic Cardiovascular Disease: Mechanisms and Emerging Therapies},
journal = {Immunological Reviews},
year = {2026},
volume = {341},
number = {1},
doi = {10.1111/imr.70151}
}
EUVIMED